A retrospective study comapring Overall survival in patients with and without brain metastases in EGFR mutation positive non-small cell lung cancer patients
Latest Information Update: 08 Jul 2021
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jul 2021 Osimertinib patent expired in 2019 and study is from January 2010 to December 2018, so included profile.
- 08 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology